PRINCETON, N.J. and SUZHOU, China, May 26, 2026 -- Transcenta Holding Ltd. (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced the receipt of a milestone payment of RMB 7 million from its HiCB (highly intensified continuous bioprocessing) platform out-licensing, alongside significant progress in its CDMO business.

Following the strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (“EirGenix”) (TWSE: 6589) executed in late 2025, and receipt of the associated upfront payment, the two companies have achieved significant technical milestones, triggering the first milestone payment. To date, Transcenta has successfully completed key deliverables. The collaboration is steadily advancing toward implementing the HiCB technology for GMP production at EirGenix’s facility.

To drive further commercialization of the HiCB platform, Transcenta recently appointed its former Chief Technology Officer (CTO), Dr. Christopher Hwang, as Head of Global Partnerships for the HiCB platform, where he will lead the global technology out-licensing strategy and oversee platform implementation. Under his leadership, Transcenta will continue to scale this non-exclusive licensing model, which allows the Company to retain full technology ownership while generating revenue from licensing fees, customized CHO culture medium optimization service, and ongoing medium supply, with proceeds reinvested into platform upgrading and the core R&D pipeline.

Concurrently, Transcenta is making steady progress in its CDMO business. The Company has recently signed new service contracts of GMP Drug Substance (DS) production for complex biologics using its HiCB processes for bioprocessing technology, as well as GMP Drug Product (DP) manufacturing for siRNA projects. Transcenta is also currently negotiating contracts for additional high-potential projects, including integrated IND development projects, siRNA GMP DP production, developability assessments, and material generation for global clients. Its CDMO revenue in the first half of 2026 will be more than doubled than the whole year number of 2025.

As the HiCB out-licensing program gains traction and the CDMO business continues to expand, Transcenta remains well-positioned to drive sustainable growth and deliver long-term value to its partners and shareholders.

About Transcenta Holding Ltd.

Transcenta Holding Ltd. (HKEX: 06628) is a global clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing.

Transcenta has established global footprint, with Headquarters and Discovery, Clinical and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in China, U.S. and Europe. Transcenta is developing a diverse pipeline of more than a dozen novel biologic therapies for oncology and selected non-oncology indications including bone and kidney disorders.

For more information, please visit www.transcenta.com and https://www.linkedin.com/company/transcenta. For inquiries regarding Business Development opportunities, please contact us at bd@transcenta.com